{
  "docId": "019de072-c7f4-719d-b60b-87ffd56a191c",
  "docSlug": "e58df8a62ccd3bd6cd3ca8f1cf8222ea",
  "documentTitle": "MindMed | Results Presentation Deck | 40 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 40,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The table uses color coding (yellow for TBD/preclinical, green for established/favorable) to highlight the developmental status of 18-MC versus the established nature of Lofexidine.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-c7f4-719d-b60b-87ffd56a191c/25",
  "deckHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c",
  "deckJsonHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c.json",
  "deckAnchorHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.14,
        "x": 0.85,
        "y": 0.92
      },
      "kind": "image",
      "text": "Maryland Opioid Research logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e216c1f-179d-4e34-a47b-7f21ff2bb835",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.18,
        "x": 0.81,
        "y": 0.01
      },
      "kind": "image",
      "text": "Johns Hopkins Medicine logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2340ebd-428e-4970-97a6-f84eac2efc24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.72,
        "x": 0.14,
        "y": 0.15
      },
      "kind": "table",
      "text": "Comparison table of 18-MC and Lofexidine across mechanism, efficacy, abuse potential, side effects, and schedule.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8081c744-5b61-473c-83a9-3f08da0d6c3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.12,
        "y": 0.05
      },
      "kind": "title",
      "text": "18-MC vs. Lofexidine",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48a2d376-4081-4b45-adb6-569f0274c053",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "7718b585-dcb0-4df9-9500-e9bf0247f6f2",
      "evidence": "table/data: Comparison table of 18-MC and Lofexidine across mechanism, efficacy, abuse potential, side effects, and schedule.",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "ec1ce69e-384a-4d30-a135-1e096a57ec8c",
      "evidence": "Side-by-side comparison table of two entities across multiple attributes.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 33,
      "from": 17,
      "beatId": "8b3edd16-18bb-4450-a68c-0765c795a4f7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 17-33 present Zolunicant as a potential solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 17,
      "name": "Trojan Horse",
      "slug": "29-trojan-horse",
      "bestFor": "Upselling, expanding scope, introducing new initiatives",
      "matchId": "35ee55af-a6fd-4477-b4a6-df3a1b7717d1",
      "evidence": "Slides 17-25 present Zolunicant as a novel solution.",
      "position": 1,
      "objective": "How can Zolunicant be a Trojan horse for addressing opioid use disorder?",
      "structure": "The Obvious Win (What They Want) -> The Hidden Opportunity -> The Bigger Vision",
      "confidence": 0.6,
      "description": "Lead with something they already want, then reveal the bigger opportunity inside"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}